arrow
S

Shintaro Hirata

Hiroshima University Hospital
H指数:39
被引数:4,657

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical phenotypes of ANCA-associated vasculitis using ensemble clustering: prognostic and therapeutic insights from two Japanese cohorts

基于集成聚类的ANCA相关性血管炎临床表型:来自两个日本队列的预后和治疗见解

2026-09-170
OAAI
Effect of different folic acid doses on methotrexate-related toxicity and its association with erythrocyte methotrexate-polyglutamates in patients with rheumatic diseases: a single-center exploratory randomized controlled trial

不同叶酸剂量对类风湿性疾病患者甲氨蝶呤相关毒性的影响及其与红细胞甲氨蝶呤多聚谷氨酸的相关性:一项单中心探索性随机对照试验

2026-06-060
OAAI
Circulating microRNAs associated with tumour necrosis factor or fibroblast-like synoviocytes predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE study

与肿瘤坏死因子或成纤维样滑膜细胞相关的循环microRNAs可预测接受甲氨蝶呤联合阿达木单抗治疗的早期类风湿关节炎患者的软骨损伤:MIRACLE研究的亚组分析

2026-03-011
PRE
Factors associated with treatment discontinuation and age-stratified safety of abatacept in Japanese patients with rheumatoid arthritis: 5-year results of the ORIGAMI study

影响日本类风湿关节炎患者阿巴西特治疗中断的因素及按年龄分层的安全性:ORIGAMI研究5年结果

2026-01-010
OA
Phenotype, serotype, and data-driven clustering reveal complementary dimensions of heterogeneity in ANCA-associated vasculitis: a multicentre Japanese cohort (J-CANVAS)

表型、血清型和数据驱动聚类揭示了ANCA相关性血管炎中异质性的互补维度:一项多中心日本队列(J-CANVAS)

2025-11-120
OAAI
Real-world effectiveness of rituximab or intravenous cyclophosphamide versus non-use in patients with severe microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective cohort study of J-CANVAS

利妥昔单抗或静脉注射环磷酰胺与非用药在重症显微镜下多血管炎和肉芽肿性多血管炎患者中的真实世界有效性:一项J-CANVAS回顾性队列研究

2025-11-010
PRE
Diabetes mellitus and cardiac disease as key predictors of rituximab-induced acute thrombocytopenia in ANCA-associated vasculitis

糖尿病和心脏疾病作为利妥昔单抗诱导的ANCA相关性血管炎急性血小板减少症的关键预测因子

2025-10-010
PRE
Myeloperoxidase-anti-neutrophil cytoplasmic antibody positivity and disease characteristics, treatment, and prognosis in eosinophilic granulomatosis with polyangiitis
2025-10-010
PRE
Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study)

方案:甲氨蝶呤联合菲尔戈替尼与菲尔戈替尼单药治疗对甲氨蝶呤反应不足的类风湿关节炎患者的多中心、前瞻性、开放标签、随机对照试验(FAITHFUL 研究)

2025-05-190
OA
Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study

不同利妥昔单抗方案治疗日本抗中性粒细胞胞浆抗体相关血管炎的缓解维持率及安全性:一项J-CANVAS研究

2025-01-110
OA
Seasonal Influence on Development of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study Conducted at Multiple Institutions in Japan ( J- CANVAS)

季节对抗中性粒细胞胞浆抗体相关血管炎发展的影响: 在日本多个机构进行的回顾性队列研究 (j-canvas)

2023-06-011
PRE
Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial
2023-04-014
OAAI